Secondly, EC subtypes with high tumor mutational burden (e.g., POLE-mutant/hypermutated and MSI-H) are highly immunogenic and exhibit more tumor-specific neoantigens, resulting in increased CD4 and CD8 tumor-infiltrating lymphocytes (TILs) and a compensatory upregulation of immune checkpoints (6). Here, CD8A is linked to neoplasm.